UnknownPhase 2 / PHASE3

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

"Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Lead sponsor

Banner Health

Asset

Thalidomide

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 12-26•Study partner/caregiver required

Primary endpoint

•Improve cognition

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID1R01AG034155-01https://reporter.nih.gov/quickSearch/1R01AG034155-01

NCT IDNCT01094340

Timeline

Milestones

Study start2010-03 (month precision)

Study first posted2010-03-26estimated

Last update posted2012-08-08estimated

Primary completion2012-12estimated (month precision)

Study completion2013-01estimated (month precision)

Assets

Drug assets

Thalidomide

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•Subjects must have a screening diagnosis of Probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.

•Subjects must have a Mini-Mental State Examination (MMSE) score of 12-26

•Subject must live at home.

•Must have a caregiver to participate in this study

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

Improve cognition

Time frame:2 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.